Medical Devices

Global Urological Cancer Drugs Market Size, Status and Forecast 2022

  • QYR1614175
  • 106 Pages
  • September 2017
  • Medical Devices
Download Sample    Get Discount   
 
This report studies the global Urological Cancer Drugs market, analyzes and researches the Urological Cancer Drugs development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like

Novartis

Pfizer

Johnson & Johnson

AstraZeneca

Astellas

Bristol-Myers Squibb

Abbott Laboratories

Celgene Corporation

Dendreon Corporation

Ferring Pharmaceuticals

GlaxoSmithKline

Indevus Pharmaceuticals Inc

Ipsen

Roche Healthcare

Sanofi S.A

Tolmar Inc

Market segment by Regions/Countries, this report covers

United States

EU

Japan

China

India

Southeast Asia

Market segment by Type, Urological Cancer Drugs can be split into

Tablets

Injection

Market segment by Application, Urological Cancer Drugs can be split into

Prostate Cancer

Bladder Cancer

Kidney Cancer

Testicular Cancer

Other

If you have any special requirements, please let us know and we will offer you the report as you want.

Table of Contents

Global Urological Cancer Drugs Market Size, Status and Forecast 2022

1 Industry Overview of Urological Cancer Drugs

1.1 Urological Cancer Drugs Market Overview

1.1.1 Urological Cancer Drugs Product Scope

1.1.2 Market Status and Outlook

1.2 Global Urological Cancer Drugs Market Size and Analysis by Regions

1.2.1 United States

1.2.2 EU

1.2.3 Japan

1.2.4 China

1.2.5 India

1.2.6 Southeast Asia

1.3 Urological Cancer Drugs Market by Type

1.3.1 Tablets

1.3.2 Injection

1.4 Urological Cancer Drugs Market by End Users/Application

1.4.1 Prostate Cancer

1.4.2 Bladder Cancer

1.4.3 Kidney Cancer

1.4.4 Testicular Cancer

1.4.5 Other

2 Global Urological Cancer Drugs Competition Analysis by Players

2.1 Urological Cancer Drugs Market Size (Value) by Players (2016 and 2017)

2.2 Competitive Status and Trend

2.2.1 Market Concentration Rate

2.2.2 Product/Service Differences

2.2.3 New Entrants

2.2.4 The Technology Trends in Future

3 Company (Top Players) Profiles

3.1 Novartis

3.1.1 Company Profile

3.1.2 Main Business/Business Overview

3.1.3 Products, Services and Solutions

3.1.4 Urological Cancer Drugs Revenue (Value) (2012-2017)

3.1.5 Recent Developments

3.2 Pfizer

3.2.1 Company Profile

3.2.2 Main Business/Business Overview

3.2.3 Products, Services and Solutions

3.2.4 Urological Cancer Drugs Revenue (Value) (2012-2017)

3.2.5 Recent Developments

3.3 Johnson & Johnson

3.3.1 Company Profile

3.3.2 Main Business/Business Overview

3.3.3 Products, Services and Solutions

3.3.4 Urological Cancer Drugs Revenue (Value) (2012-2017)

3.3.5 Recent Developments

3.4 AstraZeneca

3.4.1 Company Profile

3.4.2 Main Business/Business Overview

3.4.3 Products, Services and Solutions

3.4.4 Urological Cancer Drugs Revenue (Value) (2012-2017)

3.4.5 Recent Developments

3.5 Astellas

3.5.1 Company Profile

3.5.2 Main Business/Business Overview

3.5.3 Products, Services and Solutions

3.5.4 Urological Cancer Drugs Revenue (Value) (2012-2017)

3.5.5 Recent Developments

3.6 Bristol-Myers Squibb

3.6.1 Company Profile

3.6.2 Main Business/Business Overview

3.6.3 Products, Services and Solutions

3.6.4 Urological Cancer Drugs Revenue (Value) (2012-2017)

3.6.5 Recent Developments

3.7 Abbott Laboratories

3.7.1 Company Profile

3.7.2 Main Business/Business Overview

3.7.3 Products, Services and Solutions

3.7.4 Urological Cancer Drugs Revenue (Value) (2012-2017)

3.7.5 Recent Developments

3.8 Celgene Corporation

3.8.1 Company Profile

3.8.2 Main Business/Business Overview

3.8.3 Products, Services and Solutions

3.8.4 Urological Cancer Drugs Revenue (Value) (2012-2017)

3.8.5 Recent Developments

3.9 Dendreon Corporation

3.9.1 Company Profile

3.9.2 Main Business/Business Overview

3.9.3 Products, Services and Solutions

3.9.4 Urological Cancer Drugs Revenue (Value) (2012-2017)

3.9.5 Recent Developments

3.10 Ferring Pharmaceuticals

3.10.1 Company Profile

3.10.2 Main Business/Business Overview

3.10.3 Products, Services and Solutions

3.10.4 Urological Cancer Drugs Revenue (Value) (2012-2017)

3.10.5 Recent Developments

3.11 GlaxoSmithKline

3.12 Indevus Pharmaceuticals Inc

3.13 Ipsen

3.14 Roche Healthcare

3.15 Sanofi S.A

3.16 Tolmar Inc

4 Global Urological Cancer Drugs Market Size by Type and Application (2012-2017)

4.1 Global Urological Cancer Drugs Market Size by Type (2012-2017)

4.2 Global Urological Cancer Drugs Market Size by Application (2012-2017)

4.3 Potential Application of Urological Cancer Drugs in Future

4.4 Top Consumer/End Users of Urological Cancer Drugs

5 United States Urological Cancer Drugs Development Status and Outlook

5.1 United States Urological Cancer Drugs Market Size (2012-2017)

5.2 United States Urological Cancer Drugs Market Size and Market Share by Players (2016 and 2017)

6 EU Urological Cancer Drugs Development Status and Outlook

6.1 EU Urological Cancer Drugs Market Size (2012-2017)

6.2 EU Urological Cancer Drugs Market Size and Market Share by Players (2016 and 2017)

7 Japan Urological Cancer Drugs Development Status and Outlook

7.1 Japan Urological Cancer Drugs Market Size (2012-2017)

7.2 Japan Urological Cancer Drugs Market Size and Market Share by Players (2016 and 2017)

8 China Urological Cancer Drugs Development Status and Outlook

8.1 China Urological Cancer Drugs Market Size (2012-2017)

8.2 China Urological Cancer Drugs Market Size and Market Share by Players (2016 and 2017)

9 India Urological Cancer Drugs Development Status and Outlook

9.1 India Urological Cancer Drugs Market Size (2012-2017)

9.2 India Urological Cancer Drugs Market Size and Market Share by Players (2016 and 2017)

10 Southeast Asia Urological Cancer Drugs Development Status and Outlook

10.1 Southeast Asia Urological Cancer Drugs Market Size (2012-2017)

10.2 Southeast Asia Urological Cancer Drugs Market Size and Market Share by Players (2016 and 2017)

11 Market Forecast by Regions, Type and Application (2017-2022)

11.1 Global Urological Cancer Drugs Market Size (Value) by Regions (2017-2022)

11.1.1 United States Urological Cancer Drugs Revenue and Growth Rate (2017-2022)

11.1.2 EU Urological Cancer Drugs Revenue and Growth Rate (2017-2022)

11.1.3 Japan Urological Cancer Drugs Revenue and Growth Rate (2017-2022)

11.1.4 China Urological Cancer Drugs Revenue and Growth Rate (2017-2022)

11.1.5 India Urological Cancer Drugs Revenue and Growth Rate (2017-2022)

11.1.6 Southeast Asia Urological Cancer Drugs Revenue and Growth Rate (2017-2022)

11.2 Global Urological Cancer Drugs Market Size (Value) by Type (2017-2022)

11.3 Global Urological Cancer Drugs Market Size by Application (2017-2022)

12 Urological Cancer Drugs Market Dynamics

12.1 Urological Cancer Drugs Market Opportunities

12.2 Urological Cancer Drugs Challenge and Risk

12.2.1 Competition from Opponents

12.2.2 Downside Risks of Economy

12.3 Urological Cancer Drugs Market Constraints and Threat

12.3.1 Threat from Substitute

12.3.2 Government Policy

12.3.3 Technology Risks

12.4 Urological Cancer Drugs Market Driving Force

12.4.1 Growing Demand from Emerging Markets

12.4.2 Potential Application

13 Market Effect Factors Analysis

13.1 Technology Progress/Risk

13.1.1 Substitutes

13.1.2 Technology Progress in Related Industry

13.2 Consumer Needs Trend/Customer Preference

13.3 External Environmental Change

13.3.1 Economic Fluctuations

13.3.2 Other Risk Factors

14 Research Finding/Conclusion

15 Appendix

Methodology

Analyst Introduction

Data Source

List of Tables and Figures

Figure Urological Cancer Drugs Product Scope

Figure Global Urological Cancer Drugs Market Size (Million USD) (2012-2017)

Table Global Urological Cancer Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)

Figure Global Urological Cancer Drugs Market Share by Regions in 2016

Figure United States Urological Cancer Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)

Figure EU Urological Cancer Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)

Figure Japan Urological Cancer Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)

Figure China Urological Cancer Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)

Figure India Urological Cancer Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)

Figure Southeast Asia Urological Cancer Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)

Figure Global Urological Cancer Drugs Market Share by Type in 2016

Figure Tablets Market Size (Million USD) and Growth Rate (2012-2017)

Figure Injection Market Size (Million USD) and Growth Rate (2012-2017)

Figure Global Urological Cancer Drugs Market Share by Application in 2016

Table Key Downstream Customer in Prostate Cancer

Figure Urological Cancer Drugs Market Size (Million USD) and Growth Rate in Prostate Cancer (2012-2017)

Table Key Downstream Customer in Bladder Cancer

Figure Urological Cancer Drugs Market Size (Million USD) and Growth Rate in Bladder Cancer (2012-2017)

Table Key Downstream Customer in Kidney Cancer

Figure Urological Cancer Drugs Market Size (Million USD) and Growth Rate in Kidney Cancer (2012-2017)

Table Key Downstream Customer in Testicular Cancer

Figure Urological Cancer Drugs Market Size (Million USD) and Growth Rate in Testicular Cancer (2012-2017)

Table Key Downstream Customer in Other

Figure Urological Cancer Drugs Market Size (Million USD) and Growth Rate in Other (2012-2017)

Table Urological Cancer Drugs Market Size (Million USD) by Players (2016 and 2017)

Figure Urological Cancer Drugs Market Size Share by Players in 2016

Figure Urological Cancer Drugs Market Size Share by Players in 2017

Table Novartis Basic Information List

Table Urological Cancer Drugs Business Revenue (Million USD) of Novartis (2012-2017)

Figure Novartis Urological Cancer Drugs Business Revenue Market Share in 2016

Table Pfizer Basic Information List

Table Urological Cancer Drugs Business Revenue (Million USD) of Pfizer (2012-2017)

Figure Pfizer Urological Cancer Drugs Business Revenue Market Share in 2016

Table Johnson & Johnson Basic Information List

Table Urological Cancer Drugs Business Revenue (Million USD) of Johnson & Johnson (2012-2017)

Figure Johnson & Johnson Urological Cancer Drugs Business Revenue Market Share in 2016

Table AstraZeneca Basic Information List

Table Urological Cancer Drugs Business Revenue (Million USD) of AstraZeneca (2012-2017)

Figure AstraZeneca Urological Cancer Drugs Business Revenue Market Share in 2016

Table Astellas Basic Information List

Table Urological Cancer Drugs Business Revenue (Million USD) of Astellas (2012-2017)

Figure Astellas Urological Cancer Drugs Business Revenue Market Share in 2016

Table Bristol-Myers Squibb Basic Information List

Table Urological Cancer Drugs Business Revenue (Million USD) of Bristol-Myers Squibb (2012-2017)

Figure Bristol-Myers Squibb Urological Cancer Drugs Business Revenue Market Share in 2016

Table Abbott Laboratories Basic Information List

Table Urological Cancer Drugs Business Revenue (Million USD) of Abbott Laboratories (2012-2017)

Figure Abbott Laboratories Urological Cancer Drugs Business Revenue Market Share in 2016

Table Celgene Corporation Basic Information List

Table Urological Cancer Drugs Business Revenue (Million USD) of Celgene Corporation (2012-2017)

Figure Celgene Corporation Urological Cancer Drugs Business Revenue Market Share in 2016

Table Dendreon Corporation Basic Information List

Table Urological Cancer Drugs Business Revenue (Million USD) of Dendreon Corporation (2012-2017)

Figure Dendreon Corporation Urological Cancer Drugs Business Revenue Market Share in 2016

Table Ferring Pharmaceuticals Basic Information List

Table Urological Cancer Drugs Business Revenue (Million USD) of Ferring Pharmaceuticals (2012-2017)

Figure Ferring Pharmaceuticals Urological Cancer Drugs Business Revenue Market Share in 2016

Table GlaxoSmithKline Basic Information List

Table Urological Cancer Drugs Business Revenue (Million USD) of GlaxoSmithKline (2012-2017)

Figure GlaxoSmithKline Urological Cancer Drugs Business Revenue Market Share in 2016

Table Indevus Pharmaceuticals Inc Basic Information List

Table Urological Cancer Drugs Business Revenue (Million USD) of Indevus Pharmaceuticals Inc (2012-2017)

Figure Indevus Pharmaceuticals Inc Urological Cancer Drugs Business Revenue Market Share in 2016

Table Ipsen Basic Information List

Table Urological Cancer Drugs Business Revenue (Million USD) of Ipsen (2012-2017)

Figure Ipsen Urological Cancer Drugs Business Revenue Market Share in 2016

Table Roche Healthcare Basic Information List

Table Urological Cancer Drugs Business Revenue (Million USD) of Roche Healthcare (2012-2017)

Figure Roche Healthcare Urological Cancer Drugs Business Revenue Market Share in 2016

Table Sanofi S.A Basic Information List

Table Urological Cancer Drugs Business Revenue (Million USD) of Sanofi S.A (2012-2017)

Figure Sanofi S.A Urological Cancer Drugs Business Revenue Market Share in 2016

Table Tolmar Inc Basic Information List

Table Urological Cancer Drugs Business Revenue (Million USD) of Tolmar Inc (2012-2017)

Figure Tolmar Inc Urological Cancer Drugs Business Revenue Market Share in 2016

Table Global Urological Cancer Drugs Market Size (Million USD) by Type (2012-2017)

Figure Global Urological Cancer Drugs Market Size Share by Type in 2012

Figure Global Urological Cancer Drugs Market Size Share by Type in 2013

Figure Global Urological Cancer Drugs Market Size Share by Type in 2014

Figure Global Urological Cancer Drugs Market Size Share by Type in 2015

Figure Global Urological Cancer Drugs Market Size Share by Type in 2016

Figure Global Urological Cancer Drugs Market Size Share by Type in 2017

Table Global Urological Cancer Drugs Market Size (Million USD) by Application (2012-2017)

Figure Global Urological Cancer Drugs Market Size (Million USD) by Application in 2012

Figure Global Urological Cancer Drugs Market Size (Million USD) by Application in 2013

Figure Global Urological Cancer Drugs Market Size (Million USD) by Application in 2014

Figure Global Urological Cancer Drugs Market Size (Million USD) by Application in 2015

Figure Global Urological Cancer Drugs Market Size (Million USD) by Application in 2016

Figure Global Urological Cancer Drugs Market Size (Million USD) by Application in 2017

Table Top Consumer/End Users of Urological Cancer Drugs

Figure United States Urological Cancer Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)

Table United States Urological Cancer Drugs Market Size (Million USD) by Players (2012-2017)

Figure United States Urological Cancer Drugs Market Size Share by Players in 2016

Figure United States Urological Cancer Drugs Market Size Share by Players in 2017

Figure EU Urological Cancer Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)

Table EU Urological Cancer Drugs Market Size (Million USD) by Players (2012-2017)

Figure EU Urological Cancer Drugs Market Size Share by Players in 2016

Figure EU Urological Cancer Drugs Market Size Share by Players in 2017

Figure Japan Urological Cancer Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)

Table Japan Urological Cancer Drugs Market Size (Million USD) by Players (2012-2017)

Figure Japan Urological Cancer Drugs Market Size Share by Players in 2016

Figure Japan Urological Cancer Drugs Market Size Share by Players in 2017

Figure China Urological Cancer Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)

Table China Urological Cancer Drugs Market Size (Million USD) by Players (2012-2017)

Figure China Urological Cancer Drugs Market Size Share by Players in 2016

Figure China Urological Cancer Drugs Market Size Share by Players in 2017

Figure India Urological Cancer Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)

Table India Urological Cancer Drugs Market Size (Million USD) by Players (2012-2017)

Figure India Urological Cancer Drugs Market Size Share by Players in 2016

Figure India Urological Cancer Drugs Market Size Share by Players in 2017

Figure Southeast Asia Urological Cancer Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)

Table Southeast Asia Urological Cancer Drugs Market Size (Million USD) by Players (2012-2017)

Figure Southeast Asia Urological Cancer Drugs Market Size Share by Players in 2016

Figure Southeast Asia Urological Cancer Drugs Market Size Share by Players in 2017

Figure Global Urological Cancer Drugs Market Size (Million USD) by Regions (2017-2022)

Table Global Urological Cancer Drugs Market Size (Million USD) by Regions (2017-2022)

Figure Global Urological Cancer Drugs Market Size Share by Regions in 2017

Figure Global Urological Cancer Drugs Market Size Share by Regions in 2022

Figure United States Urological Cancer Drugs Revenue (Million USD) and Growth Rate (2017-2022)

Figure EU Urological Cancer Drugs Revenue (Million USD) and Growth Rate (2017-2022)

Figure Japan Urological Cancer Drugs Revenue (Million USD) and Growth Rate (2017-2022)

Figure China Urological Cancer Drugs Revenue (Million USD) and Growth Rate (2017-2022)

Figure India Urological Cancer Drugs Revenue (Million USD) and Growth Rate (2017-2022)

Figure Southeast Asia Urological Cancer Drugs Revenue (Million USD) and Growth Rate (2017-2022)

Table Global Urological Cancer Drugs Market Size (Million USD) by Type (2017-2022)

Figure Global Urological Cancer Drugs Market Size Share by Type in 2017

Figure Global Urological Cancer Drugs Market Size Share by Type in 2022

Table Global Urological Cancer Drugs Market Size (Million USD) by Application (2017-2022)

Figure Global Urological Cancer Drugs Market Size (Million USD) by Application in 2017

Figure Global Urological Cancer Drugs Market Size (Million USD) by Application in 2022

 
Purchase Options

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Need More Information

Similar Reports

Medical Implants Market By Type (Orthopedic Implants, cardiac implants, Stents, Spinal Implants, Neurostimulators, dental implants, Breast Implants, facial Implants) and By Materials (Metallic, Ceramic, Polymers, Natural) - Global Opportunity Analysis and Industry Forecast, 2014 - 2022

Medical implants are permanent devices such as pacemakers or temporary devices such as fracture plates which are removed once their function is completed. These implants are made up of bone, tissue, skin, ceramics, metals, plastics, and other natural materials...

  • Publish Date: August 21, 2016
  • $5370
Ostomy Drainage Bags Market by Type (Colostomy Bags, Ileostomy Bags, Urostomy Bags, Continent Urostomy Bags, and Continent Ileostomy Bags) - Global Opportunity Analysis and Industry Forecast, 2014-2022

Ostomy is a surgery wherein an artificial opening, known as stoma, is created from the colon in the human body to eliminate body wastes such as urine, mucus, and stools, which are collected in artificial bags called ostomy drainage bags. These plastic/rub...

  • Publish Date: December 1, 2016
  • $5370